Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
For patients with Stage III NSCLC with ROS1 alterations, would you avoid consolidation durvalumab after chemoradiation?
Related Questions
Would you ever consider repeating chemoradiation for patients with locally recurrent small cell lung cancer after prior chemoradiation for LS-SCLC?
For patients with metastatic thymic carcinoma, is there a role for local treatment options such as SBRT for oligoprogressive or oligopersistent disease after systemic therapy?
How do you decide between Neoadjuvant (Checkmate 816) and Peri-adjuvant (Keynote 671) chemoimmunotherapy for early stage NSCLC?
In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with Osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?
How would you manage a left sided triple negative breast cancer with a concurrent left sided locally advanced non-small cell lung cancer?
What initial therapy do you offer elderly patients with metastatic NSCLC with MET amplification and PD-L1 >50%?
What is your preferred first line approach to patients with Stage IV non-squamous NSCLC with good performance status, no driver mutations, PD-L1 low-positive, and CKD IIIB or worse, CrCl < 45 mL/min?
Has the MARS data for mesothelioma changed whether you would recommend surgery for these patients?
What are strategies to deal with grade 3/4 anorexia associated with Osimertinib?
How would you approach a patient with limited stage SCLC who progressed immediately after completing chemoradiation with brain metastasis?
